A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neoplasms|Breast Neoplasms
Interventions: DRUG: PD-0332991|DRUG: PD-0332991|DRUG: letrozole|DRUG: PD-0332991|DRUG: letrozole
Sponsor: Pfizer